Figure (Tye00 0000 01)
Tyenne Injection, Solution, Concentrate
Product Images NDC 65219-592
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Tyenne (NDC 65219-592). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Fresenius Kabi Usa, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Principal Display Panel – 80 mg /4 mL Vial Carton (Tye00 0000 02)
This is a description for the medication "Tocilizumab-aazg", which is administered via intravenous infusion. The medication comes in a single-dose vial containing 80 mg of the active ingredient. The inactive ingredients include Arginine, Histidine, Lactic acid, Polysorbate 80, and Sodium chloride in Water for Injection USP. It is recommended to store the medication refrigerated at 36°F to 46°F and protect it from light, freezing, or shaking. The prescribing information provides details regarding the recommended dosage. The carton also includes a Medication Guide for each patient. It is important to contact a doctor for medical advice about any side effects. Additionally, the medication is manufactured by Fresenius Kabi USA LLC and is a product of Austria.*
Principal Display Panel – 200 mg /10 mL Vial Carton (Tye00 0000 03)
This text provides detailed information about a medication called Tocilizumab-aazg, available in an injectable form with 200 mg/10 ml strength for intravenous infusion. The packaging consists of a single-dose vial containing the active ingredient Tocilizumab-aazg and other inactive ingredients. It includes instructions on dosage, storage at a refrigerated temperature, and advice on reporting side effects. The product is manufactured by Fresenius Kabi and should not be used if the seal is broken or missing. Overall, this text serves as a guide for healthcare providers and patients on the proper use of Tocilizumab-aazg.*
Principal Display Panel – 400 mg /20 mL Vial Carton (Tye00 0000 04)
This text is detailing the information related to a medication named "Tyenne" in the form of an injection containing tocilizumab-aazg at a concentration of 400 mg per 20 mL. It is meant for intravenous infusion only after dilution. The package includes a single-dose vial, Prescribing Information, and Medication Guide. The storage instructions advise refrigeration between 36°F to 46°F to protect the product. The contents of the vial include active and inactive ingredients listed, and it emphasizes the importance of following the prescribed dosage. The medication is manufactured by Fresenius Kabi and requires refrigeration immediately after purchase to maintain its sterile solution without preservatives.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
